The study's clinical endpoints are: basic safety, viral load in the blood and CD4 and CD8 cell counts. The analysis aims to permit ABIVAX to narrow the dose and frequency of administration for the subsequent clinical phase IIb study development planned for the next half of 2015. Professor Hartmut Ehrlich, M.D., CEO of ABIVAX, stated: ‘We are pleased with the progress we are making with ABX464, and we are confident that 2015 is a pivotal year because of this flagship product.We look forward to reporting the data from this Phase IIa study, particularly ABX464's ability to produce a sustained decrease inviral load.Accuri Cytometers announces completion of $6 million Series E preferred stock financing Accuri Cytometers, Inc., a world leader in providing life science experts with easy-to-use, cost-effective circulation cytometers, today announced completion of a $6 million Series E preferred stock financing. Program co-handled by Credit Suisse. An interview with Dr Matt SilverHPV research partnership signed between Beckman Coulter and IncellDxImproved outcomes yielded from new ChIP-seq protocol’Fueled by our continued sales development in the U.S.